HIKESHI

Across TCGA pan-cancer cohorts, HIKESHI mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HIKESHI data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher HIKESHI mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HIKESHI expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where HIKESHI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.449	1.000	.010	40	view →
CCRCC	DFS	Median	IV	0.220	0.781	.017	16	view →
LUAD	OS	Quartile	II,III,IV	0.659	1.000	.004	10	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	OS	Median	All	1.000	0.922	.012	4	view →
HNSC	OS	Median	II,III,IV	0.800	0.623	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HIKESHI–UCEC (OS)

Open the UCEC breakdown →